Regional State Healthcare Institution Smolensk Regional Clinical Hospital Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2013
NCT01889433
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Regional State Budgetary Healthcare Institution "Smolensk Regional Clinical Hospital"

Active Ingredients

Drugs in Phase 3 Trials (2)

interferon alpha-2b (Intron-A) (1 trial)

molixan (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hepatitis (Phase 3)

Hepatitis A (Phase 3)

Hepatitis C (Phase 3)

Hepatitis C, Chronic (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2